Get the Stockscreener App
8.31
30.87%
1.96
Olema Pharmaceuticals Inc stock is traded at $8.31, with a volume of 3.84M.
It is up +30.87% in the last 24 hours and up +54.75% over the past month.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
See More
Previous Close:
$6.35
Open:
$6.35
24h Volume:
3.84M
Relative Volume:
5.08
Market Cap:
$570.35M
Revenue:
-
Net Income/Loss:
$-96.66M
P/E Ratio:
-3.8651
EPS:
-2.15
Net Cash Flow:
$-83.73M
1W Performance:
+52.20%
1M Performance:
+54.75%
6M Performance:
+95.07%
1Y Performance:
-29.75%
1-Day Range:
$6.35
$8.44
1-Week Range:
$5.36
$8.44
52-Week Range:
$2.86
$13.93
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Name
Olema Pharmaceuticals Inc
Sector
Industry
Phone
(415) 651-3316
Address
780 BRANNAN STREET, SAN FRANCISCO
Compare OLMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
8.31 | 435.83M | 0 | -96.66M | -83.73M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-25 | Reiterated | Citigroup | Buy |
| Apr-02-24 | Initiated | Goldman | Buy |
| Jan-30-24 | Initiated | Citigroup | Buy |
| Jul-21-23 | Initiated | Oppenheimer | Outperform |
| May-05-23 | Initiated | CapitalOne | Overweight |
| Feb-22-23 | Initiated | Credit Suisse | Outperform |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Jun-09-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-28-22 | Initiated | H.C. Wainwright | Neutral |
| Dec-07-21 | Resumed | Cowen | Outperform |
| Dec-14-20 | Initiated | Canaccord Genuity | Buy |
| Dec-14-20 | Initiated | Cowen | Outperform |
| Dec-14-20 | Initiated | JP Morgan | Overweight |
| Dec-14-20 | Initiated | Jefferies | Buy |
View All
Olema Pharmaceuticals Inc Stock (OLMA) Latest News
What data driven models say about Olema Pharmaceuticals Inc.’s futureTrade Analysis Report & Daily Risk Controlled Trade Plans - Newser
What MACD and RSI say about Olema Pharmaceuticals Inc.Market Activity Report & Growth Oriented Trade Recommendations - Newser
Identifying reversal signals in Olema Pharmaceuticals Inc.July 2025 Opening Moves & Fast Moving Trade Plans - Newser
Signal strength of Olema Pharmaceuticals Inc. stock in tech scannersJuly 2025 Outlook & Free Technical Pattern Based Buy Signals - Newser
Will Olema Pharmaceuticals Inc. stock recover after earningsJuly 2025 Earnings & AI Enhanced Trading Alerts - خودرو بانک
Can Olema Pharmaceuticals Inc. maintain its current growth rate2025 Volume Leaders & Technical Buy Zone Confirmation - خودرو بانک
Is Olema Pharmaceuticals Inc. a play on infrastructure spendingJuly 2025 Chart Watch & Fast Gaining Stock Reports - خودرو بانک
Paradigm Biocapital Advisors LP Sells 563,798 Shares of Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Oppenheimer Reaffirms "Outperform" Rating for Olema Pharmaceuticals (NASDAQ:OLMA) - MarketBeat
Olema Pharmaceuticals shares surge 20.49% intraday after announcing clinical trial collaboration with Pfizer for breast cancer treatment. - AInvest
How high can Olema Pharmaceuticals Inc. stock goJuly 2025 Setups & AI Enhanced Trading Signals - Newser
Olema Pharmaceuticals, Inc. $OLMA Shares Sold by BVF Inc. IL - MarketBeat
Olema Pharmaceuticals, Inc. $OLMA is Bain Capital Life Sciences Investors LLC's 8th Largest Position - MarketBeat
Regression analysis insights on Olema Pharmaceuticals Inc. performanceJuly 2025 Update & Daily Entry Point Alerts - Newser
Multi factor analysis applied to Olema Pharmaceuticals Inc.Earnings Growth Summary & Free Expert Approved Momentum Trade Ideas - Newser
Olema Pharmaceuticals Inc. recovery potential after sell offQuarterly Market Review & Long Hold Capital Preservation Plans - Newser
Olema Pharmaceuticals Inc. stock outlook for YEAR2025 Macro Impact & Free Accurate Trade Setup Notifications - Newser
Is Olema Pharmaceuticals Inc. trending in predictive chart modelsTrade Risk Assessment & Long-Term Safe Return Strategies - Newser
Is Olema Pharmaceuticals Inc. stock poised for growthJuly 2025 Fed Impact & Smart Money Movement Tracker - Newser
How to read the order book for Olema Pharmaceuticals Inc.Portfolio Value Summary & AI Based Buy/Sell Signal Reports - Newser
Is Olema Pharmaceuticals Inc. a top pick in the sectorStock Surge & Safe Capital Growth Trade Ideas - خودرو بانک
Published on: 2025-09-05 21:58:24 - خودرو بانک
Why Olema Pharmaceuticals Inc. is moving todayJuly 2025 Summary & Scalable Portfolio Growth Methods - Newser
Does Olema Pharmaceuticals Inc. outperform in volatile markets2025 Fundamental Recap & Smart Allocation Stock Reports - خودرو بانک
Pfizer collaboration with Olema may spark future bidding waranalyst - MSN
Olema Pharmaceuticals Inc. stock trendline breakdown2025 Analyst Calls & Long-Term Safe Investment Plans - Newser
Will Olema Pharmaceuticals Inc. stock hit new highs in YEARJuly 2025 Price Swings & Daily Price Action Insights - خودرو بانک
Olema Oncology’s Strategic Use of Equity Incentives to Fuel R&D and Talent Growth - AInvest
Oppenheimer maintains Olema stock rating, sees Pfizer deal as strategic By Investing.com - Investing.com Canada
Olema Pharmaceuticals Grants Stock Options to New Employees Under 2022 Inducement Plan - Quiver Quantitative
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
124,000 Shares: Olema Oncology Grants New Employee Stock Options with 4-Year Vesting Terms - Stock Titan
Wellington Management Group LLP Lowers Holdings in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Pfizer's partnership with Olema may spark a bidding war for the biotech firm. - AInvest
Pfizer (PFE) Partners With Olema For New Metastatic Breast Cancer Study - simplywall.st
Is Olema Pharmaceuticals Inc. likely to announce a buybackJuly 2025 Intraday Action & Weekly Sector Rotation Insights - khodrobank.com
When is the best time to exit Olema Pharmaceuticals Inc.Gap Down & High Conviction Buy Zone Picks - Newser
H.C. Wainwright reiterates Buy rating on Olema Pharmaceuticals stock By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Buy rating on Olema Pharmaceuticals stock - Investing.com
How does Olema Pharmaceuticals Inc. correlate with NasdaqTrade Volume Summary & Safe Capital Allocation Plans - خودرو بانک
What technical models suggest about Olema Pharmaceuticals Inc.’s comeback2025 Top Gainers & Verified Short-Term Trading Plans - Newser
Olema Pharmaceuticals Inc Stock (OLMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):